UK Implements Emergency Ban on Puberty Blockers for Minors

The three-month prohibition affects private prescriptions and follows a critical review of gender identity services.

The ban applies to private prescribers in England, Wales, Scotland, and registered EEA or Swiss prescribers.
Existing patients under 18 who have been on puberty blockers for at least six months can continue their prescriptions.
The decision follows the Cass Review, which found weak evidence supporting the safety and efficacy of puberty blockers for minors.
The NHS had already halted new puberty blocker treatments for minors based on the review's findings.
Controversy surrounds the ban, with some organizations criticizing it as harmful to transgender youth.